The role of somatostatin and octreotide in bowel obstruction: Pre-clinical and clinical results

C. Ripamonti, C. Panzeri, L. Groff, G. Galeazzi, R. Boffi

Research output: Contribution to journalArticle

Abstract

Malignant bowel obstruction is a common complication in patients with advanced abdominal or pelvic cancer. Whereas surgery should be considered in all cases of malignant bowel obstruction, many advanced and terminal cancer patients are considered unfit for surgery. In such patients with a short life expectancy, gastrointestinal symptoms such as nausea, vomiting, continuous and/or colicky pain, can be controlled by using a pharmacologic approach made up of analgesics, antiemetics and antisecretory drugs, without the use of a venting nasogastric tube. Among the antisecretory drugs, octreotide has been shown to reduce nausea and vomiting in bowel-obstructed patients owing to a reduction of gastrointestinal secretions, thus allowing in most patients removal of the nasogastric tube and the associated distress. Preclinical and clinical studies that demonstrated the role of somatostatin and octreotide in bowel obstruction are reviewed.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalTumori
Volume87
Issue number1
Publication statusPublished - 2001

Keywords

  • Bowel obstruction
  • Clinical
  • Experimental
  • Octreotide
  • Somatostatin

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'The role of somatostatin and octreotide in bowel obstruction: Pre-clinical and clinical results'. Together they form a unique fingerprint.

  • Cite this